Results 131 to 140 of about 3,981,458 (213)

Chemotherapy effects on brain glucose metabolism at rest [PDF]

, 2011
Background: A growing number of studies reports that chemotherapy may impair brain functions inducing cognitive changes which can persist in a subset of cancer survivors.
Riccardo Torta, Elisabetta Geda, Bruno Baudino, Katiuscia Sacco, Gianni Bisi, Federico D'Agata, Giancarlo Castellano, Laura Orsi, Simona Cauda, Rita Ardito, Lorys Castelli, Matteo Manfredi, Paola Caroppo, Antonella Parente, Franco Cauda   +14 more
core  

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models

Cancer Science, Volume 117, Issue 11, Page 2997-3006, November 2026.
Dietary NA restriction converts the effect of NAMPT inhibition from cytostatic to cytotoxic in SCLC in vivo. ABSTRACT Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models ...
Kyoji Tsurumi, Miyuki Nomura, Mai Ouchi, Shigehiro Yagishita, Naohiko Kikuchi, Taku Sato, Mami Morita, Yoji Yamashita, Kayoko Hayashi, Tomoyoshi Soga, Akinobu Hamada, Tatsuro Fukuhara, Nobuhiro Tanuma   +12 more
wiley   +1 more source

Treatment of chemotherapy-induced thrombocytopenia with monotherapy versus combination therapy: the devil is in the details. [PDF]

Res Pract Thromb Haemost, 2023
Al-Samkari H.
europepmc   +1 more source

Design to Dose: Integrating Quantitative Insights Across the Antibody Drug Conjugate (ADC) Development Lifecycle

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) are among the most pharmacologically complex therapeutics in clinical development. Their behavior emerges from the interplay of antibody disposition, linker stability, payload pharmacology, and host physiology—interdependencies that render qualitative descriptors such as “stronger affinity” or “more potent ...
Daniel Bending, Eshita Khera, Inez Lam, Innocent G. Asiimwe, Venkatesh Pilla Reddy   +4 more
wiley   +1 more source

Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis. [PDF]

BMC Pharmacol Toxicol, 2023
Chen W, Liu Y, Li L, Zeng X.
europepmc   +1 more source

Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas   +3 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors. [PDF]

Res Pract Thromb Haemost, 2023
Xia X, Zhou H, Zhang H, Deng W, Li R, Huang Q, Wang Y, Xiong H.   +7 more
europepmc   +1 more source